Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their ...

On the heels of her reelection in July, European Commission President Ursula von der Leyen tasked her new ...

A group of four Republicans on the House Committee on Energy and Commerce called for more transparency of clinical trial data ...

The FDA has cleared Iterum’s oral antibiotic for certain patients with uncomplicated urinary tract infections (uUTIs) who ...

Agomab Therapeutics is benefiting from Sanofi’s push to become an immunology powerhouse. The Antwerp-based biotech said ...

Nascent clinical biotech Septerna added to the slight uptick in IPO fervor this fall with its $288 million Nasdaq listing on ...

Bristol Myers Squibb and Ideaya Biosciences both released detailed snapshots of early-stage data for cancer drugs targeting ...

Elucida Oncology, a clinical-stage biotech led by former Pfizer executive Geno Germano, has shut down, Endpoints News has ...

Alto Neuroscience’s stock tumbled 60% on Wednesday morning, the day after the company said a mid-stage trial for its oral ...

Tom Frohlich has signed on as CEO of autoimmune disease specialist Jade Biosciences, a company in the Paragon portfolio that ...

The future of Telix Pharmaceuticals' new spinout Rhine Pharma hinges on the outcome of one early-stage trial, Telix CEO ...

The promise of a one-and-done CRISPR infusion is beginning to look more real than ever. On Thursday, Intellia Therapeutics ...